Home / Business and Economy / Repligen Buys BioLife for $1.5B Cell Therapy Boost
Repligen Buys BioLife for $1.5B Cell Therapy Boost
22 Jul
Summary
- Repligen acquires BioLife Solutions in a $1.5 billion cash-and-stock deal.
- The acquisition aims to expand Repligen's footprint in cell therapy.
- BioLife Solutions provides tools and services for the cell and gene therapy market.
Repligen Corp has announced its intention to acquire BioLife Solutions Inc. in a substantial deal valued at around $1.5 billion. The transaction, structured as a combination of cash and stock, is designed to significantly enhance Repligen's presence in the dynamic and rapidly growing cell therapy market.
BioLife Solutions is a key player in the cell and gene therapy (CGT) sector, specializing in the development and provision of vital tools and services. Their offerings are instrumental in maintaining the integrity and functionality of biological materials throughout the complex processes of collection, development, manufacturing, and distribution of new therapies.
Key products from BioLife Solutions include their specialized CryoStor freeze media and HypoThermosol hypothermic storage media, engineered to preserve cells critical for CGT applications. The company also offers the Sexton cell processing product line, featuring human platelet lysates (hPL) for cell expansion, and CellSeal closed systems designed for CGT applications. Furthermore, their product portfolio includes CryoCase cryo-compatible containers and ThawSTAR automated thawing devices for frozen therapies.
This acquisition by Repligen underscores the increasing strategic importance of the cell therapy market and highlights BioLife Solutions' established role in supporting its advancement.
